Business Description
Basilea Pharmaceutica Ltd
ISIN : CH0011432447
Share Class Description:
FRA:PK5: Registered SharesTotal Employee Number:
189Description
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.07 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.51 | |||||
Debt-to-EBITDA | 1.32 | |||||
Interest Coverage | 20.8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.1 | |||||
3-Year EBITDA Growth Rate | 24.6 | |||||
3-Year EPS without NRI Growth Rate | 45.5 | |||||
3-Year FCF Growth Rate | 139.8 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.98 | |||||
9-Day RSI | 73.8 | |||||
14-Day RSI | 73.23 | |||||
3-1 Month Momentum % | -0.36 | |||||
6-1 Month Momentum % | -5.56 | |||||
12-1 Month Momentum % | 13.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.6 | |||||
Quick Ratio | 5.97 | |||||
Cash Ratio | 4.17 | |||||
Days Inventory | 279.91 | |||||
Days Sales Outstanding | 21.64 | |||||
Days Payable | 155.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | 2.18 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.66 | |||||
Operating Margin % | 23.88 | |||||
Net Margin % | 21.17 | |||||
EBITDA Margin % | 25.61 | |||||
FCF Margin % | 22.23 | |||||
OCF Margin % | 23.4 | |||||
ROE % | 39.94 | |||||
ROA % | 18.96 | |||||
ROIC % | 48.15 | |||||
3-Year ROIIC % | -92.56 | |||||
ROC (Joel Greenblatt) % | 232.51 | |||||
ROCE % | 26.22 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.85 | |||||
Forward PE Ratio | 17.32 | |||||
PE Ratio without NRI | 15.85 | |||||
Price-to-Owner-Earnings | 16.76 | |||||
PS Ratio | 3.51 | |||||
PB Ratio | 4.85 | |||||
Price-to-Tangible-Book | 4.85 | |||||
Price-to-Free-Cash-Flow | 15.7 | |||||
Price-to-Operating-Cash-Flow | 14.92 | |||||
EV-to-EBIT | 11.34 | |||||
EV-to-Forward-EBIT | 5.46 | |||||
EV-to-EBITDA | 11.01 | |||||
EV-to-Forward-EBITDA | 10.88 | |||||
EV-to-Revenue | 2.82 | |||||
EV-to-Forward-Revenue | 2.72 | |||||
EV-to-FCF | 12.89 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Projected-FCF | 9.07 | |||||
Price-to-Median-PS-Value | 1 | |||||
Price-to-Graham-Number | 1.85 | |||||
| Price-to-Net-Current-Asset-Value | 5.7 | |||||
| Price-to-Net-Cash | 21.05 | |||||
Earnings Yield (Greenblatt) % | 8.82 | |||||
FCF Yield % | 7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Basilea Pharmaceutica Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 266.846 | ||
| EPS (TTM) (€) | 4.328 | ||
| Beta | 0.1064 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.69 | ||
| Volatility % | 26.22 | ||
| 14-Day RSI | 73.23 | ||
| 14-Day ATR (€) | 1.004565 | ||
| 20-Day SMA (€) | 61.53 | ||
| 12-1 Month Momentum % | 13.02 | ||
| 52-Week Range (€) | 47.8 - 69.6 | ||
| Shares Outstanding (Mil) | 12.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Basilea Pharmaceutica Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Basilea Pharmaceutica Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Basilea Pharmaceutica Ltd Frequently Asked Questions
What is Basilea Pharmaceutica Ltd(FRA:PK5)'s stock price today?
The current price of FRA:PK5 is €67.60. The 52 week high of FRA:PK5 is €69.60 and 52 week low is €47.80.
When is next earnings date of Basilea Pharmaceutica Ltd(FRA:PK5)?
The next earnings date of Basilea Pharmaceutica Ltd(FRA:PK5) is .
Does Basilea Pharmaceutica Ltd(FRA:PK5) pay dividends? If so, how much?
Basilea Pharmaceutica Ltd(FRA:PK5) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics | 2019-04-24 |
Articles on Basilea Pharmaceutica Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers